Professor Andrew McLachlan

BPharm PhD, FPS FACP MCPA MSHPA
Chair of Pharmacy (Aged Care) based at Concord
Professor of Pharmacy (Aged Care)

A15 - Pharmacy And Bank Building
The University of Sydney

Telephone +61 2 9351 4452; Concord +61 2 9767 7373
Fax +61 2 9351 6950

Website Related website

Biographical details

Andrew is a pharmacist, academic, teacher and researcher with experience in clinical and experimental pharmacology and research into the quality use of medicines. He is Professor of Pharmacy (Aged Care) in the Faculty of Pharmacy at the University of Sydney based at Concord Hospital. His research focuses on understanding the causes and consequences of variability in response to medicines and how this informs the quality use of medicines.

Research interests

Translating research in clinical pharmacology into practice in older people. Understanding the causes and consequences of variability in response to medicines and how this informs the quality use of medicines. The focus of this research has been in special patient populations such as older people, very young and critically ill.

This includes specific projects on:

  • The impact of ageing on drug disposition and response to medicines
  • Optimising pain management in older people
  • Ethnic differences in drug response
  • Herb-drug interactions
  • Genetic basis of response to medicines
  • Optimising anticancer therapies by understanding PK and PD variability
  • Therapeutic drug monitoring as a tool to optimized drug therapy
  • Optimal anticoagulant use in older people
  • Quality use of medicines
  • Quality and safety in medication management
  • Optimal treatment of low back pain

Teaching and supervision

Undergraduate and postgraduate teaching in pharmacy practice including experiential placements in the hospital setting.

PHAR 5512 – Clinical Residency 2

PHAR 7112 - Healthy Ageing Pharmacy Practice

Associations

Editorial Board Membership

British Journal of Clinical Pharmacology (Executive Editor, 2008 - ongoing)

Journal of Pharmacy Practice and Research (Associate Editor, 2007 - ongoing)

Journal of Pharmacokinetics and Pharmacodynamics (2006-2009)

Journal of Pharmacy and Pharmacology (2004-2008)

Drug Information Journal (2003-2008)

Australian Medicines Handbook (2001 - 2011)

Australian Medicines Handbook, Aged Care Companion Australian Pharmaceutical Formulary and Handbook (2008-2012)

University Service

Associate Dean (Research), Faculty of Pharmacy (2010 - 2012)

Member, SEG-Research Committee, University of Sydney (2010 - 2012)

Chair, Postgraduate Coursework Subcommittee and Deputy Chair, Combined Board of Postgraduate Studies in Dentistry, Medicine and Pharmacy (2000-2008)

Director (Clinical Studies), Herbal Medicines Research and Education Centre, University of Sydney (2003 - 2011)

Associate Dean (Postgraduate) and Chair, Postgraduate Committee, Faculty of Pharmacy (2000-2005)

Hospital Service Member (and now Chair), Sydney Local Health District – Concord Hospital, Human Research Ethics Committee (2007 - ongoing)

Member, Drug and Therapeutics Committee, Concord Hospital (2006 – ongoing)

Professional & Community Contributions

Chair, National Medicines Policy Committee (2009 - 2012)

Member, National Medicines Policy Executive (2009 - 2012)

President, Australasian Pharmaceutical Science Association (APSA) (2009-2012)

Pharmaceutical Subcommittee, Advisory Committee on Prescription Medicines (2002 - ongoing)

Member, Australian Therapeutic Goods Advisory Council (2012 – ongoing)

Member (and now Chair), Australian Sports Anti-Doping Authority, Anti-Doping Rule Violation Panel (2010 – ongoing)

Member, Medication Reference Group, Australian Commission on Safety and Quality in Healthcare (ACSQHC)

Awards and honours

Pharmaceutical Society of Australia, Pharmacist of the Year 2006

Keywords

Clinical pharmacology; Mental health; Ageing; Cardiovascular diseases

Selected grants

2014

  • Centre of Research Excellence in Medicines and Ageing; McLachlan A, Pearson S, Banks E, Preen D, Le Couteur D, Dobbins T, Etherton-Beer C, Buckley N, Viney R, Henry D; National Health and Medical Research Council (NHMRC)/Centres of Research Excellence.
  • Phase 1 clinical trial: Inhaled rifapentine for rapid treatment of tuberculosis; Chan K, McLachlan A, Chan J, Parumasivam T; Rebecca L Cooper Medical Research Foundation/Equipment Grant.
  • EVOS® FL Auto cell imaging system; Nicholson G, Clark G, Zhou H, Jessup W, Le Couteur D, McMahon A, McLachlan A, Allan C, Handelsman D, Hart D, Walters K, Kritharides L, Kockx M, Kennerson M, Cooper M, Seibel M, Verma N, Silveira P, Fromm P, Simanainen U, Cogger V, Zheng Y; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • Pregabalin in addition to usual care for sciatica (PRECISE): a randomised, placebo-controlled trial; Lin C, Maher C, McLachlan A, Latimer J, Koes B, Hancock M, Harris I; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Patterns of care and health outcomes: Opportunities for epidemiology and health services research using whole of population, cross-jurisdictional linkage of routinely collected data; Aranda S, Currow D, Pearson S, Young J, Armstrong B, O'Connell D, McLachlan A, Le Couteur D, Buckley N; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • A randomised controlled trial of deprescribing to optimise medical therapy for frail older people: the Opti-Med study; Hilmer S, Naganathan V, McLachlan A, Comans T, Etherton-Beer C, Potter K; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • High risk prescribing in older Australians; Banks E, Le Couteur D, Pearson S, McLachlan A, Viney R, Hilmer S, Gnjidic D, Blyth F; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • Improving the use of chemotherapy by targeting the inflammatory response; Clarke S, Robertson G, Piquette-Miller M, McLachlan A, Baker M, Katsifis A; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • Lessors Learned Form Reporting Dispensing near Miss Incidents in Community Pharmacy; Fois R, Chen T, McLachlan A; Pharmaceutical Defence Limited (PDL)/Research Grant.
  • Organic anion transporting polypeptide 1A2 pharmocogenetcs in the determination of personalized treatment protocols with imatinib; Zhou F, Murray M, McLachlan A; Pharmacy Research Trust of NSW/Research Support.
  • RES: Updating information contained in The University of Sydney, Herb-Drug Interaction Database (2013-044); McLachlan A, Duke C, Roufogalis B; UnityHealth Pty Ltd/Research Support.
  • Development of personalised dosage protocols for tyrosine kinase inhibitors in oncology patients; Murray M, Gurney H, McLachlan A; Cancer Council New South Wales/Research Project Grants.
  • Optimising pain management in frail older people; McLachlan A, Naganathan V, Le Couteur D, Hilmer S, Gibson S; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The first placebo-controlled trial of paracetamol for back pain; Latimer J, Maher C, McLachlan A, Day R, Cooper C, Hancock M; National Health and Medical Research Council (NHMRC)/Project Grants.

2008

  • Inter-Ethnic Differences in Tolerance of Anti-Cancer drugs; Clarke S, McLachlan A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Optimising pain management in the frail older people; McLachlan A; University of Sydney/Bridging Support.

2006

  • Quality Indicators for Best Practice Approaches to Experiential Placements in Pharmacy programs.; Hotham L, Davey A, McLachlan A, Brien J, Chaar B, March G, McAteer S, Stupans I; Carrick Institute of Teaching and Learning/Discipline Initiative Grant.

2005

  • A clinical trial of manipulative therapy and/or NSAIDs for significant acute low back pain; Maher C, Latimer J, McLachlan A, Cooper C; National Health and Medical Research Council (NHMRC)/Project Grants.

2003

  • Interactions between herbal medicines and the anticoagulant warfarin; Ammit A, Duke C, McLachlan A, Roufogalis B; National Health and Medical Research Council (NHMRC)/Project Grants.
  • A community pharmacy based anticoalgulant management service; McLachlan A, Krass I, Chen T; Pharmacy Guild of Australia/Research Grant.

2001

  • The effects of ageing on cancer chemotherapy; Rivory L, Clarke S, McLachlan A; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Books

  • Duke, C., Goh, P., McLachlan, A., Roufogalis, B. (2001). Complementary Medicines. Australia: Pharmaceutical Society of Australia.

Book Chapters

  • Clarke, S., McLachlan, A. (2012). Interaction Between Complementary and Alternative Medicines and Conventional Medicines. In Olver, I and Robotin, M (Eds.), Perspectives on Complementary and Alternative Medicines, (pp. 227-259). London: Imperial College Press.
  • Clarke, S., McLachlan, A., Brown, D., Carbonara, S., Kissane, R. (2010). Beyond Conventional Cancer Treatments: The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians. In Monica Robotin, Ian Olver and Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physician's Handbook, (pp. 285-315). London: Imperial College Press.
  • McLachlan, A., Hilmer, S., Le Couteur, D. (2010). Dosing Errors: Age-Related Changes in Pharmacokinetics. In Susan Koch, F. Michael Gloth, and Rhonda Nay (Eds.), Medication Management in Older Adults: A Concise Guide for Clinicians, (pp. 127-135). New York: Springer Science + Business Media.
  • McLachlan, A., Ramzan, I. (2010). Misuse of Formulations in the Aged Care Setting. In Susan Koch, F. Michael Gloth, and Rhonda Nay (Eds.), Medication Management in Older Adults: A Concise Guide for Clinicians, (pp. 95-104). New York: Springer Science + Business Media.
  • Le Couteur, D., Kendig, H., Naganathan, V., McLachlan, A. (2010). The Ethics of Prescribing Medications to Older People. In Susan Koch, F. Michael Gloth, and Rhonda Nay (Eds.), Medication Management in Older Adults: A Concise Guide for Clinicians, (pp. 29-42). New York: Springer Science + Business Media.

Journals

  • McLachlan, A., Nguyen, T., Hassali, M. (2014). Generic medicines policies in the Asia Pacific region: ways forward. WHO South-East Asia Journal of Public Health, 2(1), 72-74.
  • Abdel Shaheed, C., Maher, C., Williams, K., McLachlan, A. (2014). Interventions available over the counter and advice for acute low back pain: Systematic review and meta-analysis. The Journal of Pain, 15(1), 2-15. [More Information]
  • Dolton, M., Perera, V., Pont, L., McLachlan, A. (2014). Terbinafine in combination for the treatment of resistant or refractory mycoses: Investigating optimal dosing regimens using a physiologically-based pharmacokinetic model. Antimicrobial Agents and Chemotherapy, 58(1), 48-54. [More Information]
  • Dolton, M., Perera, V., Pont, L., McLachlan, A. (2014). Terbina�?ne in Combination with Other Antifungal Agents for Treatment of Resistant or Refractory Mycoses: Investigating Optimal Dosing Regimens Using a Physiologically Based Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 58(1), 48-54. [More Information]
  • Perera, V., Gross, A., Forrest, A., Landersdorfer, C., Xu, H., Ait-Oudhia, S., McLachlan, A. (2013). A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. Drug Metabolism and Disposition, 41(11), 1957-1966. [More Information]
  • Lehnbom, E., McLachlan, A., Brien, J. (2013). A Qualitative Study of Swedes' Opinions about Shared Electronic Health Records. Studies in Health Technology and Informatics, 192, 3-7. [More Information]
  • Rogers, K., Kemp, A., McLachlan, A., Blyth, F. (2013). Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PLoS One, 8(12), 1-13. [More Information]
  • Perera, V., Gross, A., Polasek, T., Qin, Y., Rao, G., Forrest, A., Xu, J., McLachlan, A. (2013). Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert opinion on drug metabolism & toxicology, 9(9), 1115-1137. [More Information]
  • Perera, V., Gross, A., McLachlan, A. (2013). Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans. Journal of Pharmacy and Pharmacology, 65(2), 264-270. [More Information]
  • Kim, E., Chen, Y., Huang, J., Li, K., Razmovski-Naumovski, V., Poon, J., Chan, K., Roufogalis, B., McLachlan, A., Mo, S., Liu, Z., Li, G., et al (2013). Evidence-based toxicity evaluation and scheduling of Chinese herbal medicines. Journal of Ethnopharmacology, 146(1), 40-61. [More Information]
  • Svistounov, D., Oteiza, A., Zykova, S., Sorensen, K., McCourt, P., McLachlan, A., McCuskey, R., Smedsrod, B. (2013). Hepatic disposal of advanced glycation end products during maturation and aging. Experimental Gerontology, 48(6), 549-556. [More Information]
  • Gnjidic, D., Le Couteur, D., Pearson, S., McLachlan, A., Viney, R., Hilmer, S., Blyth, F., Joshy, G., Banks, E. (2013). High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health, 13, 1-9. [More Information]
  • Best, O., Gnjidic, D., Hilmer, S., Naganathan, V., McLachlan, A. (2013). Investigating polypharmacy and drug burden index in hospitalised older people. Internal Medicine Journal, 43(8), 912-918. [More Information]
  • Vardy, J., Dhillon, H., Clarke, S., Olesen, I., Leslie, F., Warby, A., Beith, J., Sullivan, A., Hamilton, A., Beale, P., Rittau, A., McLachlan, A. (2013). Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. SpringerPlus, 2(1), 1-5. [More Information]
  • El-Samman, F., Chaar, B., McLachlan, A., Aslani, P. (2013). Medicines and disease information needs of older Arabic-speaking Australians. Australasian Journal on Ageing, 32(1), 28-33. [More Information]
  • Williams, C., Maher, C., Latimer, J., McLachlan, A., Hancock, M., Day, R., Billot, L., Lin, C. (2013). PACE - the first placebo controlled trial of paracetamol for acute low back pain: statistical analysis plan. Trials, 14(1), 1-9. [More Information]
  • Black, L., McLachlan, A., Griffith, J., Higgins, D., Gillett, A., Krockenberger, M., Govendir, M. (2013). Pharmacokinetics of chloramphenicol following administration of intravenous and subcutaneous chloramphenicol sodium succinate, and subcutaneous chloramphenicol, to koalas (Phascolarctos cinereus). Journal of Veterinary Pharmacology and Therapeutics, 36(5), 478-485. [More Information]
  • Johnston, C., Kirkpatrick, C., McLachlan, A., Hilmer, S. (2013). Physiologically Based Pharmacokinetic Modeling at the Extremes of Age. Clinical Pharmacology and Therapeutics, 93(2), 148-148. [More Information]
  • Mathieson, S., Maher, C., McLachlan, A., Latimer, J., Koes, B., Hancock, M., Harris, I., O Day, R., Pik, J., Jan, S., Billot, L., Lin, C. (2013). PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. Trials, 14(1), 1-8. [More Information]
  • Dolton, M., McLachlan, A. (2013). Reply to "What Types of Candida Infections Should Be Included When Evaluating Breakthrough Infections during Posaconazole Prophylaxis?". Antimicrobial Agents and Chemotherapy, 57(6), 2906-2906. [More Information]
  • Gnjidic, D., Le Couteur, D., Blyth, F., Travison, T., Rogers, K., Naganathan, V., Cumming, R., Waite, L., Seibel, M., Handelsman, D., McLachlan, A., Hilmer, S. (2013). Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open, 3(3), 1-10. [More Information]
  • Dolton, M., Ray, J., McLachlan, A. (2013). Telaprevir and Boceprevir: A Potential Role for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 35(3), 414-415. [More Information]
  • Saqf el Hait, S., Basheti, I., McLachlan, A., Overland, J., Chaar, B. (2013). The role of pharmacists in the management of Arabic-speaking people with diabetes mellitus: A systematic review. Journal of Pharmaceutical Health Services Research, 4(4), 239-248. [More Information]
  • Phalen, D., Frimberger, A., Pyecroft, S., Peck, S., Harmsen, C., Lola, S., De Mello Mattos, B., Li, K., McLachlan, A., Moore, A. (2013). Vincristine Chemotherapy Trials and Pharmacokinetics in Tasmanian Devils with Tasmanian Devil Facial Tumor Disease. PLoS One, 8(6), 1-7. [More Information]
  • Lehnbom, E., McLachlan, A., Brien, J. (2012). A qualitative study of Australians' opinions about personally controlled electronic health records. Studies in Health Technology and Informatics, 178, 105-110. [More Information]
  • Le Couteur, D., Robinson, M., Leverton, A., Creasey, H., Waite, L., Atkins, K., McLachlan, A. (2012). Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease. Australasian Journal on Ageing, 31(3), 164-169. [More Information]
  • Le Couteur, D., McLachlan, A., Quinn, R., Simpson, S., De Cabo, R. (2012). Aging biology and novel targets for drug discovery. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 67A(2), 168-174. [More Information]
  • Le Couteur, D., McLachlan, A., De Cabo, R. (2012). Aging, Drugs, and Drug Metabolism. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 67A(2), 137-139. [More Information]
  • Robertson, J., Santoso, B., Holloway, K., Dartnell, J., Tisocki, K., McLachlan, A., Smith, A. (2012). Asia Pacific Conference on National Medicines Policies. Australian Prescriber, 35(6), 190-193.
  • Giam, J., McLachlan, A., Krass, I. (2012). Characterizing specialized compounding in community pharmacies. Research in Social and Administrative Pharmacy, 8(3), 240-252. [More Information]
  • McLachlan, A., Pont, L. (2012). Drug Metabolism in Older People - A Key Consideration in Achieving Optimal Outcomes With Medicines. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 67A(2), 175-180. [More Information]
  • Pinto, R., Maher, C., Ferreira, M., Ferreira, P., Hancock, M., Oliveira, V., McLachlan, A., Koes, B. (2012). Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. BMJ, 344, 1-15. [More Information]
  • Pinto, R., Maher, C., Ferreira, M., Hancock, M., Oliveira, V., McLachlan, A., Koes, B., Ferreira, P. (2012). Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Annals of Internal Medicine, 157(12), 865-877. [More Information]
  • Dolton, M., Roufogalis, B., McLachlan, A. (2012). Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion-Transporting Polypeptides. Clinical Pharmacology and Therapeutics, 92(5), 622-630. [More Information]
  • Gnjidic, D., Hilmer, S., Blyth, F., Naganathan, V., Cumming, R., Handelsman, D., McLachlan, A., Abernethy, D., Banks, E., Le Couteur, D. (2012). High-Risk Prescribing and Incidence of Frailty Among Older Community-Dwelling Men. Clinical Pharmacology and Therapeutics, 91(3), 521-528. [More Information]
  • Bell, S., Le Couteur, D., McLachlan, A., Chen, T., Moles, R., Basger, B., Hilmer, S. (2012). Improving medicine selection for older people: Do we need an Australian classification for inappropriate medicines use? Australian Family Physician, 41(1/2), 9-10. [More Information]
  • Perera, V., Gross, A., McLachlan, A. (2012). Influence of Environmental and Genetic Factors on CYP1A2 Activity in Individuals of South Asian and European Ancestry. Clinical Pharmacology and Therapeutics, 92(4), 511-519. [More Information]
  • Rittau, A., McLachlan, A. (2012). Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling. Journal of Pharmacy and Pharmacology, 64(5), 705-711. [More Information]
  • Perera, V., Gross, A., McLachlan, A. (2012). Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe. Current Drug Metabolism, 13(5), 667-678. [More Information]
  • Dolton, M., Ray, J., Chen, S., Ng, K., Pont, L., McLachlan, A. (2012). Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response and Factors Affecting Concentration. Antimicrobial Agents and Chemotherapy, 56(11), 5503-5510. [More Information]
  • Dolton, M., Ray, J., Chen, S., Ng, K., Pont, L., McLachlan, A. (2012). Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 56(9), 4793-4799. [More Information]
  • Gnjidic, D., Hilmer, S., Blyth, F., Naganathan, V., Waite, L., Seibel, M., McLachlan, A., Cumming, R., Handelsman, D., Le Couteur, D. (2012). Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of Clinical Epidemiology, 65(9), 989-995. [More Information]
  • Dolton, M., Ray, J., Marriott, D., McLachlan, A. (2012). Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrobial Agents and Chemotherapy, 56(6), 2806-2813. [More Information]
  • Dolton, M., Pont, L., Stevens, G., McLachlan, A. (2012). Prevalence of potentially harmful drug interactions in older people in Australian aged-care facilities. Journal of Pharmacy Practice and Research, 42(1), 33-36.
  • Lowres, N., Freedman, B., Redfern, J., McLachlan, A., Krass, I., Bennett, A., Briffa, T., Bauman, A., Neubeck, A. (2012). Screening Education And Recognition in Community pHarmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged >65 years (SEARCH-AF stroke prevention study): a cross-sectional study protocol. BMJ Open, 2(3), 1-6. [More Information]
  • Mitchell, S., Huizer-Pajkos, A., Cogger, V., McLachlan, A., Le Couteur, D., Jones, B., De Cabo, R., Hilmer, S. (2012). The Influence of Old Age and Poloxamer-407 on the Hepatic Disposition of Diazepam in the Isolated Perfused Rat Liver. Pharmacology: international journal of experimental and clinical pharmacology, 90(5-6), 233-241. [More Information]
  • Stocker, S., McLachlan, A., Savic, R., Kirkpatrick, C., Graham, G., Williams, K., Day, R. (2012). The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology, 74(3), 477-489. [More Information]
  • Mitchell, S., Huizer-Pajkos, A., Cogger, V., McLachlan, A., Le Couteur, D., Jones, B., De Cabo, R., Hilmer, S. (2011). Age-Related Pseudocapillarization of the Liver Sinusoidal Endothelium Impairs the Hepatic Clearance of Acetaminophen in Rats. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 66A(4), 400-408. [More Information]
  • Phan, V., Tan, C., Rittau, A., Xu, H., McLachlan, A., Clarke, S. (2011). An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 7(11), 1395-1410. [More Information]
  • Stafford, L., Peterson, G., Bereznicki, L., Jackson, S., van Tienen, E., Angley, M., Bajorek, B., McLachlan, A., Mullan, J., Misan, G., et al (2011). Clinical Outcomes of a Collaborative, Home-Based Postdischarge Warfarin Management Service. The Annals of Pharmacotherapy, 45(3), 325-334. [More Information]
  • McLachlan, A., Bath, S., Naganathan, V., Hilmer, S., Le Couteur, D., Gibson, S., Blyth, F. (2011). Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. British Journal of Clinical Pharmacology, 71(3), 351-364. [More Information]
  • He, X., Clarke, S., McLachlan, A. (2011). Clinical pharmacology of chemotherapy agents in older people with cancer. Current Gerontology and Geriatrics Research, 2011, 628670-1-628670-6. [More Information]
  • Giam, J., McLachlan, A., Krass, I. (2011). Community pharmacy compounding-impact on professional status. International Journal of Clinical Pharmacy, 33(2), 177-182. [More Information]
  • Le Couteur, D., Banks, E., Gnjidic, D., McLachlan, A. (2011). Deprescribing. Australian Prescriber, 34(6), 182-185.
  • Chaar, B., Brien, J., Hanrahan, J., McLachlan, A., Penm, J., Pont, L. (2011). Experimental Education in Australian Pharmacy: Preceptors' Perspectives. Pharmacy Education, 11(1), 166-171.
  • Clarke, S., McLachlan, A. (2011). Interaction between complementary and alternative medicine with conventional anti-cancer medicine. Cancer Forum, 35(1), 18-23.
  • Stocker, S., Graham, G., McLachlan, A., Williams, K., Day, R. (2011). Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with Gout. Journal of Rheumatology, 38(5), 904-910. [More Information]
  • Perera, V., Gross, A., Xu, H., McLachlan, A. (2011). Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. Journal of Pharmacy and Pharmacology, 63(9), 1161-1168. [More Information]
  • Mitchell, S., Huizer-Pajkos, A., Cogger, V., McLachlan, A., Le Couteur, D., Hilmer, S. (2011). Poloxamer 407 Increases the Recovery of Paracetamol in the Isolated Perfused Rat Liver. Journal of Pharmaceutical Sciences, 100(1), 334-340. [More Information]
  • Nishtala, S., McLachlan, A., Bell, J., Chen, T. (2010). A retrospective study of drug-related problems in Australian aged care homes: medication reviews involving pharmacists and general practitioners. Journal of Evaluation in Clinical Practice, 17, 97-103. [More Information]
  • Williams, C., Maher, C., Hancock, M., McLachlan, A., McAuley, J., Latimer, J. (2010). Appropriate Discard of "Best" Practice Guidelines for Acute Low Back Pain. Archives of Internal Medicine, 170(12), 1088-1088.
  • Perera, V., Gross, A., McLachlan, A. (2010). Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomedical Chromatography, 24(10), 1136-1144. [More Information]
  • Wilk, V., Palmer, H., Stosic, R., McLachlan, A. (2010). Evidence and Practice in the Self-Management of Low Back Pain: Findings From an Australian Internet-based Survey. Clinical Journal of Pain, 26(6), 533-540. [More Information]
  • Le Couteur, D., Ford, G., McLachlan, A. (2010). Evidence, Ethics and Medication Management in Older People. Journal of Pharmacy Practice and Research, 40(2), 148-152.
  • Perera, V., Hilmer, S., McLachlan, A. (2010). Frailty should be assessed using validated scales. Drugs and Aging, 27(8), 687. [More Information]
  • McLachlan, A. (2010). Generic medicines literacy - minimising the potential for patient confusion. Medical Journal of Australia, 192(7), 368-369. [More Information]
  • Williams, C., Maher, C., Hancock, M., McAuley, J., McLachlan, A., Britt, H., Fahridin, S., Harrison, C., Latimer, J. (2010). Low Back Pain and Best Practice Care - A Survey of General Practice Physicians. Archives of Internal Medicine, 170(3), 271-277. [More Information]
  • Stocker, S., Franklin, M., Anderson, J., Pillans, P., Williams, K., McLachlan, A., Day, R., Taylor, P. (2010). Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 878, 2363-2368. [More Information]
  • Williams, C., Latimer, J., Maher, C., McLachlan, A., Cooper, C., Hancock, M., Day, R., McAuley, J., Lin, C. (2010). PACE - The first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial. BMC Musculoskeletal Disorders, 11, 169-1-169-6. [More Information]
  • Mohammed Abdul, M., Jiang, X., Williams, K., Day, R., Roufogalis, B., Liauw, W., Xu, H., Matthias, A., Lehmann, R., McLachlan, A. (2010). Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. British Journal of Clinical Pharmacology, 69(5), 508-515. [More Information]
  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Joshua, D., et al (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69(5), 484-497. [More Information]
  • Zeng, L., Blair, E., Nath, C., Shaw, P., Earl, J., Stephen, K., Montgomery, K., Coakley, J., Hodson, E., Stormon, M., McLachlan, A. (2010). Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. British Journal of Clinical Pharmacology, 70(4), 567-579. [More Information]
  • Giam, J., McLachlan, A., Krass, I. (2010). Specialized compounding in community pharmacies: Organizational perspective. Journal of the American Pharmacists Association, 50, 354-361. [More Information]
  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2010). The participation of cytochrome P450 3A4 in clozapine biotransformation is detected in people with schizophrenia by high-throughput in vivo phenotyping. Journal of Clinical Psychopharmacology, 30(5), 629-631. [More Information]
  • Duque, G., Close, J., de Jager, J., Ebeling, P., Inderjeeth, C., Lord, S., McLachlan, A., Reid, I., Troen, B. (2010). Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention. Medical Journal of Australia, 193(3), 173-179. [More Information]
  • Dolton, M., Xu, H., Cheong, E., Maitz, P., Kennedy, P., Gottlieb, T., Buono, E., McLachlan, A. (2010). Vancomycin pharmacokinetics in patients with severe burn injuries. Burns, 36(4), 469-476. [More Information]
  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2009). A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Therapeutic Drug Monitoring, 31(2), 239-246. [More Information]
  • Nishtala, S., Fois, R., McLachlan, A., Bell, J., Kelly, P., Chen, T. (2009). Anticholinergic Activity of Commonly Prescribed Medications and Neuropsychiatric Adverse Events in Older People. The Journal of Clinical Pharmacology, 49, 1176-1184. [More Information]
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Day, R., Davies, R. (2009). Can predictors of response to NSAIDs Be identified in patients with acute low back pain? Clinical Journal of Pain, 25(8), 659-665. [More Information]
  • Mitchell, S., Hilmer, S., McLachlan, A. (2009). Clinical pharmacology of analgesics in old age and frailty. Reviews in Clinical Gerontology, 19(2), 103-118. [More Information]
  • Fois, R., Mewes, B., McLachlan, A., Ramzan, I. (2009). Compounded medicines and 'off label' prescribing - A case for more guidance. Australian Family Physician, 38(1/2), 16-20. [More Information]
  • Nishtala, S., McLachlan, A., Bell, J., Chen, T. (2009). Determinants of Antidepressant Medication Prescribing in Elderly Residents of Aged Care Homes in Australia: A Retrospective Study. The American Journal of Geriatric Pharmacotherapy: the peer-reviewed journal of geriatric drug therapy, 7(4), 210-219. [More Information]
  • Nishtala, S., McLachlan, A., Bell, J., Chen, T. (2009). Determinants of antipsychotic medication use among older people living in aged care homes in Australia. International Journal of Geriatric Psychiatry, , 1-9. [More Information]
  • Hong, P., Moore, M., McLachlan, A., Piquette-Miller, M., Xu, H., Clarke, S. (2009). Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 5(3), 243-257. [More Information]
  • Zeng, L., Nath, C., Shaw, P., Earl, J., McLachlan, A. (2009). HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. Biomedical Chromatography, 23(1), 92-100. [More Information]
  • Nishtala, S., Hilmer, S., McLachlan, A., Hannan, P., Chen, T. (2009). Impact of Residential Medication Management Reviews on Drug Burden Index in Aged-Care Homes - A Retrospective Analysis. Drugs and Aging, 26(8), 677-686. [More Information]
  • Xu, H., Murray, M., McLachlan, A. (2009). Influence of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Sulfonylurea Drugs. Current Drug Metabolism, 10(6), 643-658. [More Information]
  • Zeng, L., Nath, C., Blair, E., Shaw, P., Stephen, K., Earl, J., Coakley, J., McLachlan, A. (2009). Population Pharmacokinetics of Acyclovir in Children and Young People with Malignancy after Administration of Intravenous Acyclovir or Oral Valacyclovir. Antimicrobial Agents and Chemotherapy, 53(7), 2918-2927. [More Information]
  • McLachlan, A., Hilmer, S., Le Couteur, D. (2009). Variability in response to medicines in older people: Phenotypic and genotypic factors. Clinical Pharmacology and Therapeutics, 85(4), 431-433. [More Information]
  • Su, E., Naganathan, V., Fallah, H., Bajorek, B., McLachlan, A. (2008). Anticoagulation control in hospitalised patients on warfarin. Journal of Pharmacy Practice and Research, 38(4), 292-295.
  • McLachlan, A. (2008). Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Medical Journal of Australia, 188(7), 428-429.
  • Roos, J., Kirkpatrick, C., Tett, S., McLachlan, A., Duffull, S. (2008). Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. British Journal of Clinical Pharmacology, 66(4), 455-466. [More Information]
  • Xu, H., Williams, K., Liauw, W., Murray, M., Day, R., McLachlan, A. (2008). Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology, 153(7), 1579-1586. [More Information]
  • Giam, J., McLachlan, A. (2008). Extemporaneous product use in paediatric patients: a systematic review. International Journal of Pharmacy Practice, 16, 3-10.
  • Zeng, L., Nath, C., Shaw, P., Earl, J., McLachlan, A. (2008). HPLC-fluorescence assay for acyclovir in children. Biomedical Chromatography, 22(8), 879-887. [More Information]
  • Iyer, S., Naganathan, V., McLachlan, A., Le Couteur, D. (2008). Medication Withdrawal Trials in People Aged 65 Years and Older: A Systematic Review. Drugs and Aging, 25(12), 1021-1031. [More Information]
  • Mohammed Abdul, M., Jiang, X., Williams, K., Day, R., Roufogalis, B., Liauw, W., Xu, H., McLachlan, A. (2008). Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. British Journal of Pharmacology, 154(8), 1691-1700. [More Information]
  • Stocker, S., Williams, K., McLachlan, A., Graham, G., Day, R. (2008). Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clinical Pharmacokinetics, 47(2), 111-118. [More Information]
  • Jiang, X., Galettis, P., Links, M., Mitchell, P., McLachlan, A. (2008). Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. British Journal of Clinical Pharmacology, 65(3), 326-333. [More Information]
  • Nishtala, S., McLachlan, A., Bell, J., Chen, T. (2008). Psychotropic prescribing in long-term care facilities: Impact of medication reviews and educational interventions. American Journal of Geriatric Psychiatry, 16(8), 621-632. [More Information]
  • Nath, C., McLachlan, A., Shaw, P., Coakley, J., Earl, J. (2007). Amphotericin B Dose Optimization in Children with Malignant Diseases. Chemotherapy, 53(2), 142-147. [More Information]
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2007). Assessment of diclofenac or spinal manipulation therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. The Lancet, 370(9599), 1638-1643. [More Information]
  • Day, R., Graham, G., Hicks, M., McLachlan, A., Stocker, S., Williams, K. (2007). Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clinical Pharmacokinetics, 46(8), 623-644. [More Information]
  • Hilmer, S., McLachlan, A., Le Couteur, D. (2007). Clinical pharmacology in the geriatric patient. Fundamental and Clinical Pharmacology, 21(3), 217-230. [More Information]
  • McLachlan, A. (2007). Community physiotherapy results in effective self-management of knee pain (commentary 2). Australian Journal of Physiotherapy, 53(1), 62-63.
  • Favaloro, E., Lloyd, J., Rowell, J., Baker, R., Rickard, K., Kershaw, G., Street, A., Scarff, K., Barrese, G., Maher, D., McLachlan, A. (2007). Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder - A randomised cross-over, multi-centre study. Thrombosis and Haemostasis, 97(6), 922-930. [More Information]
  • McLachlan, A., Ramzan, I., Milne, R. (2007). Frequently asked questions about generic medicines. Australian Prescriber, 30(2), 41-43.
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Pharmacology and Therapeutics, 82(1), 33-40. [More Information]
  • Bell, J., Aslani, P., McLachlan, A., Whitehead, P., Chen, T. (2007). Mental health case conferences in primary care: content and treatment decision making. Research in Social and Administrative Pharmacy, 3(1), 86-103. [More Information]
  • Hong, Y., Shaw, P., Tattam, B., Nath, C., Earl, J., Stephen, K., McLachlan, A. (2007). Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. European Journal of Clinical Pharmacology, 63(2), 165-172. [More Information]
  • Xu, H., Loboz, K., Gross, A., McLachlan, A. (2007). Stereoselective Analysis of Hydroxybupropion and Application to Drug Interaction Studies. Chirality, 19(3), 163-170. [More Information]
  • Favaloro, E., Kershaw, G., McLachlan, A., Lloyd, J. (2007). Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease. Seminars in Thrombosis and Hemostasis, 33(8), 745-758. [More Information]
  • Loboz, K., Gross, A., Williams, K., Liauw, W., Day, R., Blievernicht, J., Zanger, U., McLachlan, A. (2006). Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity. Pharmacology and Therapeutics, 80(1), 75-84. [More Information]
  • Ray, J., Keogh, A., McLachlan, A. (2006). Decision Support Tool to Individualize Cyclosporine Dose in Stable, Long-term Heart Transplant Recipients Receiving Metabolic Inhibitors: Overcoming Limitations of Cyclosporine C2 Monitoring. Journal Of Heart And Lung Transplantation, 25(10), 1223-1229. [More Information]
  • Bell, J., Whitehead, P., Aslani, P., McLachlan, A., Chen, T. (2006). Drug-Related Problems in the Community Setting - Pharmacists' Findings and Recommendations for People with Mental Illnesses. Clinical Drug Investigation, 26(7), 415-425. [More Information]
  • Jiang, X., Blair, E., McLachlan, A. (2006). Investigations of the Effects of Herbal Medicines on Warfarin Response in Healthy Subjects: A Population Pharmacokinetic-Pharmacodynamic Modeling Approach. The Journal of Clinical Pharmacology, 46(11), 1370-1378. [More Information]
  • McLachlan, A., Ramzan, I. (2006). Meals and Medicines. Australian Prescriber, 29(2), 40-42.
  • Paradisis, M., Evans, N., Kluckow, M., Osborn, D., McLachlan, A. (2006). Pilot study of milrinone for low systemic blood flow in very preterm infants. The Journal of Pediatrics, 148(3), 306-313. [More Information]
  • Paradisis, M., Jiang, X., McLachlan, A., Evans, N., Kluckow, M., Osborn, D. (2006). Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition (e ADC - F and N), 92(3), F204-F209. [More Information]
  • Hong, Y., Shaw, P., Nath, C., Yadav, S., Stephen, K., Earl, J., McLachlan, A. (2006). Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrobial Agents and Chemotherapy, 50(3), 935-942. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455.
  • Gisev, N., Bell, J., McLachlan, A., Chetty, M., Chen, T. (2006). Psychiatric Drug Use Among Patients of a Community Mental Health Service: Patterns and Implications. Disease Management and Health Outcomes, 14(6), 369-376.
  • Senner, A., Johnston, K., McLachlan, A. (2005). A Comparison of Peripheral and Centrally Collected Cyclosporine A Blood Levels in Pediatric Patients Undergoing Stem Cell Transplant. Oncology Nursing Forum, 32(1), 73-77. [More Information]
  • Ramzan, I., McLachlan, A. (2005). Anti-epileptics switching problem?. But where is the evidence? Australian Journal of Pharmacy, 86, 772-820.
  • Bell, J., McLachlan, A., Aslani, P., Whitehead, P., Chen, T. (2005). Community pharmacy services to optimise the use of medications for mental illness: a systematic review. Australia and New Zealand Health Policy, 2(29), 1-11. [More Information]
  • Jiang, X., Williams, K., Liauw, W., Ammit, A., Roufogalis, B., Duke, C., Day, R., McLachlan, A. (2005). Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology, 59(4), 425-432. [More Information]
  • Ramzan, I., McLachlan, A. (2005). Generic arguments. Australian Pharmacist, 24, 501-502.
  • Hong, Y., Ramzan, I., McLachlan, A. (2005). Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver. Journal of Pharmaceutical Sciences, 94(1), 169-176. [More Information]
  • Loboz, K., Gross, A., Ray, J., McLachlan, A. (2005). HPLC assay for bupropion and its major metabolites in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 823, 115-121. [More Information]
  • Tobin, P., Hong, Y., Seale, J., Rivory, L., McLachlan, A. (2005). Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. Journal of Pharmacy and Pharmacology, 57, 39-45. [More Information]
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2005). Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomised controlled trial [ACTRN012605000036617]. BMC Musculoskeletal Disorders, 6, 57-1-57-6. [More Information]
  • Zahir, H., McLachlan, A., Nelson, A., McCaughan, G., Gleeson, M., Akhlaghi, F. (2005). Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients. Therapeutic Drug Monitoring, 27(4), 422-430. [More Information]
  • Ray, J., Marriott, D., Bloch, M., McLachlan, A. (2005). Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. British Journal of Clinical Pharmacology, 60(3), 291-299. [More Information]
  • Pett, S., Williams, L., Day, R., Lloyd, A., Carr, A., Clezy, K., Emery, S., Kaplan, E., McPhee, D., McLachlan, A., et al (2004). A Phase I Study Of The Pharmacokinetics And Safety Of Passive Immunotherapy With Caprine Anti-Hiv Antibodies, (Pe)Hrg214, In Hiv-1-Infected Individuals. HIV Clinical Trials, 5(2), 91-98.
  • Pearce, G., McLachlan, A., Ramzan, I. (2004). Bioequivalence: How, Why and What Does it Really Mean? Journal of Pharmacy Practice and Research, 34(3), 195-200.
  • Zahir, H., McCaughan, G., Gleeson, M., Nand, R., McLachlan, A. (2004). Changes In Tacrolimus Distribution In Blood And Plasma Protein Binding Following Liver Transplantation. Therapeutic Drug Monitoring, 26(5), 506-515.
  • Hong, Y., Ramzan, I., McLachlan, A. (2004). Disposition Of Amphotericin B In The Isolated Perfused Rat Liver. Journal of Pharmacy and Pharmacology, 56(1), 35-41.
  • Mukhtar, S., Olsen, W., McLachlan, A. (2004). Dissolution Of Extemporaneous Paracetamol Capsules. Journal of Pharmacy Practice and Research, 34(4), 276-281.
  • Jiang, X., Williams, K., Liauw, W., Ammit, A., Roufogalis, B., Duke, C., Day, R., McLachlan, A. (2004). Effect Of St John's Wort And Ginseng On The Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects. British Journal of Clinical Pharmacology, 57(5), 592-599.
  • Zahir, H., McCaughan, G., Gleeson, M., Nand, R., McLachlan, A. (2004). Factors Affecting Variability In Distribution Of Tacrolimus In Liver Transplant Recipients. British Journal of Clinical Pharmacology, 57(3), 298-309.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2004). Herb-Drug Interactions: An Evidence Based Approach. Current Medicinal Chemistry, 11(11), 1513-1525.
  • Blair, E., Rivory, L., Clarke, S., McLachlan, A. (2004). Population Pharmacokinetics Of Raltitrexed In Patients With Advanced Solid Tumours. British Journal of Clinical Pharmacology, 57(4), 416-426.
  • Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53.
  • Ray, J., Keogh, A., McLachlan, A., Akhlaghi, F. (2003). Cyclosporin c2 and c0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. Journal Of Heart And Lung Transplantation, 22(7), 715-722.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). Garlic-drug interactions. The Journal of Complementary Medicine, 11, 57-59.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). Ginkgo biloba interactions. The Journal of Complementary Medicine, 11, 70-72.
  • Sasongko, L., Williams, K., Day, R., McLachlan, A. (2003). Human subcutaneous tisue distribution of fluconazole: comparison of microdialysis and suction blister techniques. British Journal of Clinical Pharmacology, 56(5), 551-561.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). Interaction or over-reaction? Journal of Alternative and Complementary Medicine: research on paradigm, practice, and policy, 11, 60-61.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). Liquorice-drug interactions. The Journal of Complementary Medicine, 11, 40-43.
  • Wren, B., Day, R., McLachlan, A., Williams, K. (2003). Pharmacokinetcs of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. Climacteric, 6(2), 104-111.
  • Tett, S., Kirkpatrick, C., Gross, A., McLachlan, A. (2003). Principles and clinical application of assessing alterations in renal elimination pathways. Clinical Pharmacokinetics, 42(14), 1193-1211. [More Information]
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). St John's wort interactions. Journal of Alternative and Complementary Medicine: research on paradigm, practice, and policy, 11, 66-68.
  • Bell, J., Aslani, P., McLachlan, A., Whitehead, P., Chen, T., Penrose-Wall, J. (2003). The role of the community pharmacist in Home Medicine Reviews and case conferences for consumers with mental disorders. Australian Journal of Pharmacy, 11, 716-719.
  • Firth, S., McDougall, F., McLachlan, A., Baxter, R. (2002). Impaired Blockade of Insulin-Like Growth Factor I (IGF-I)-Induced Hypoglycemia by IGF Binding Protein-3 Analog with Reduced Ternary Complex-Forming Ability. Endocrinology, 143(5), 1669-1676.
  • Hosseini Yeganeh, M., McLachlan, A. (2002). In-vitro distribution of terbinafine in rat and human blood. Journal of Pharmacy and Pharmacology, 54(2), 277-281.
  • Sasongko, L., Ramzan, I., Williams, K., McLachlan, A. (2002). Muscle distribution of the neuromuscular blocker gallami using microdialysis. Journal of Pharmaceutical Sciences, 91(3), 769-775. [More Information]
  • Hosseini Yeganeh, M., McLachlan, A. (2002). Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrobial Agents and Chemotherapy, 46(7), 2219-2228.
  • McLachlan, A., Gross, A., Beal, J., Minns,, I., Tett, S. (2001). Analytical validation for a series of marker compounds used to assess renal drug elimination processes. Therapeutic Drug Monitoring, 23, 39-46.
  • Sasongko, L., Ramzan, I., McLachlan, A., Williams, K. (2001). Application of a high-performance liquid chromatographic assay for the neuromuscular blocker gallamine to analysis of rat plasma, muscle and microdialysate samples. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 754, 467-475.
  • Akhalaghi, F., McLachlan, A., Keogh, A., Kaan, A. (2001). Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. Journal Of Heart And Lung Transplantation, 20(4), 431-438.
  • Nath, C., McLachlan, A., Shaw, P., Gunning,, R., Earl, J. (2001). Population pharmacokinetics of amphotericin B in children with malignant diseases. British Journal of Clinical Pharmacology, 52, 671-680.
  • McLachlan, A., Gross, A., Minns,, I., Beal, J., Tett, S. (2001). Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. British Journal of Clinical Pharmacology, 51, 547-555.
  • Hosseini Yeganeh, M., McLachlan, A. (2001). Tissue distribution of terbinafine in rats. Journal of Pharmaceutical Sciences, 90(11), 1817-1828.
  • Zahir, H., Nand, R., Brown, K., Tattam, B., McLachlan, A. (2001). Validation of methods to study the distribution and protein binding of tacrolimus in human blood. Journal of Pharmacological and Toxicological Methods, 46, 27-35.

Conferences

  • Black, L., McLachlan, A., Griffith, J., Higgins, D., Gillett, A., Krockenberger, M., Govendir, M. (2013). Pharmacokinetics of chloramphenicol in koalas (Phascolarctos cinereus). Wildlife Disease Assoc, Australasia Conference, N/A: N/A.
  • Lowres, N., Neubeck, A., Redfern, J., McLachlan, A., Krass, I., Bennett, A., Briffa, T., Salkeld, G., Brieger, D., Sy, R., Bauman, A., Freedman, B. (2013). Screening Education and Recognition in Community Pharmacies of Atrial Fibrillation to Prevent stroke (SEARCH-AF Stroke Prevention Study). 61st Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ) 2013, Gold Coast, Queensland, Australia. [More Information]
  • Fois, R., Huynh, K., Chen, T., McLachlan, A., Lalor, D., Aslani, P. (2011). Patient safety culture climate among Australian community pharmacies. 2011 Primary Health Care Research Conference, Brisbane: Primary Health Care Research and Information Service.
  • Huynh, K., Chen, T., McLachlan, A., Lalor, D., Aslani, P., Fois, R. (2010). An assessment of patient safety culture climate among Australian community pharmacies. Australasian Pharmaceutical Science Association Annual Conference (2010). Australasian Pharmaceutical Science Association.
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Day, R., Davies, R. (2009). Can Predictors of Responders to NSAIDs be Identified in Patients with Acute Low Back Pain? 10th International Forum on Primary Care Research on Low Back Pain: LBP Forum X 2009, United States: Harvard School of Public Health.
  • Eriksson, C., McLachlan, A., Chen, T., Nishtala, S., Fois, R. (2009). Selective serotonin reuptake inhibitor therapy and neurological and psychiatric adverse events. Australasian Pharmaceutical Science Association (APSA) Annual Conference (2009) Aus-CRS Symposium, Mount Waverley, Melbourne, Australia: Australasian Pharmaceutical Science Association.
  • Williams, C., Maher, C., Hancock, M., McAuley, J., McLachlan, A., Britt, H., Latimer, J. (2009). Usual care of low back pain in primary care and a comparison to evidence-based guideline recommendations. Australian Physiotherapy Association Conference Week APA 2009, Australia: Australian Physiotherapy Association.
  • Aslani, P., El Samman, F., McLachlan, A., Chaar, B. (2008). Medicine information needs of older Arabic-speaking Australians. National Medicines Symposium 2008, Canberra: Pharmaceutical Health and Rational Use of Medicines Committee.
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2007). Addition of NSAIDS and/or manipulation to advice and paracetamol does not speed recovery from acute low back pain. 9th International Forum on Primary Care Research on Low Back Pain: LBP Forum IX 2007.
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2007). Addition of NSAIDS and/or manipulation to advice and paracetamol does not speed recovery from acute low back pain. Musculoskeletal Physiotherapy Australia 15th Biennial conference 2007, Australia: Australian Physiotherapy Association.
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2005). Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomised controlled trial. Faculty of Health Science Post Graduate Research Symposium 2005, Australia: University of Sydney.
  • Bell, J., McLachlan, A., Chen, T. (2002). Evidence based assessment of pharmaceutical interventions for the treatment and prevention of osteoporosis. 12th International Social Pharmacy Workshop in Australia, Sweden: Swedish Pharmaceutical Press.
  • Sasongko, L., McLachlan, A., Williams, K., Day, R. (2001). Human skin tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. Australasian Society of Clinical nd Experimental Pharmacologists and Toxicologists Annual Scientific Meeting, : World Scientific Publishing.
  • Sainsbury, E., McLachlan, A., Aslani, P. (2001). Tools of the trade: Preparing pharmacists for professional practice.

2014

  • McLachlan, A., Nguyen, T., Hassali, M. (2014). Generic medicines policies in the Asia Pacific region: ways forward. WHO South-East Asia Journal of Public Health, 2(1), 72-74.
  • Abdel Shaheed, C., Maher, C., Williams, K., McLachlan, A. (2014). Interventions available over the counter and advice for acute low back pain: Systematic review and meta-analysis. The Journal of Pain, 15(1), 2-15. [More Information]
  • Dolton, M., Perera, V., Pont, L., McLachlan, A. (2014). Terbinafine in combination for the treatment of resistant or refractory mycoses: Investigating optimal dosing regimens using a physiologically-based pharmacokinetic model. Antimicrobial Agents and Chemotherapy, 58(1), 48-54. [More Information]
  • Dolton, M., Perera, V., Pont, L., McLachlan, A. (2014). Terbina�?ne in Combination with Other Antifungal Agents for Treatment of Resistant or Refractory Mycoses: Investigating Optimal Dosing Regimens Using a Physiologically Based Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 58(1), 48-54. [More Information]

2013

  • Perera, V., Gross, A., Forrest, A., Landersdorfer, C., Xu, H., Ait-Oudhia, S., McLachlan, A. (2013). A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. Drug Metabolism and Disposition, 41(11), 1957-1966. [More Information]
  • Lehnbom, E., McLachlan, A., Brien, J. (2013). A Qualitative Study of Swedes' Opinions about Shared Electronic Health Records. Studies in Health Technology and Informatics, 192, 3-7. [More Information]
  • Rogers, K., Kemp, A., McLachlan, A., Blyth, F. (2013). Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PLoS One, 8(12), 1-13. [More Information]
  • Perera, V., Gross, A., Polasek, T., Qin, Y., Rao, G., Forrest, A., Xu, J., McLachlan, A. (2013). Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert opinion on drug metabolism & toxicology, 9(9), 1115-1137. [More Information]
  • Perera, V., Gross, A., McLachlan, A. (2013). Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans. Journal of Pharmacy and Pharmacology, 65(2), 264-270. [More Information]
  • Kim, E., Chen, Y., Huang, J., Li, K., Razmovski-Naumovski, V., Poon, J., Chan, K., Roufogalis, B., McLachlan, A., Mo, S., Liu, Z., Li, G., et al (2013). Evidence-based toxicity evaluation and scheduling of Chinese herbal medicines. Journal of Ethnopharmacology, 146(1), 40-61. [More Information]
  • Svistounov, D., Oteiza, A., Zykova, S., Sorensen, K., McCourt, P., McLachlan, A., McCuskey, R., Smedsrod, B. (2013). Hepatic disposal of advanced glycation end products during maturation and aging. Experimental Gerontology, 48(6), 549-556. [More Information]
  • Gnjidic, D., Le Couteur, D., Pearson, S., McLachlan, A., Viney, R., Hilmer, S., Blyth, F., Joshy, G., Banks, E. (2013). High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health, 13, 1-9. [More Information]
  • Best, O., Gnjidic, D., Hilmer, S., Naganathan, V., McLachlan, A. (2013). Investigating polypharmacy and drug burden index in hospitalised older people. Internal Medicine Journal, 43(8), 912-918. [More Information]
  • Vardy, J., Dhillon, H., Clarke, S., Olesen, I., Leslie, F., Warby, A., Beith, J., Sullivan, A., Hamilton, A., Beale, P., Rittau, A., McLachlan, A. (2013). Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. SpringerPlus, 2(1), 1-5. [More Information]
  • El-Samman, F., Chaar, B., McLachlan, A., Aslani, P. (2013). Medicines and disease information needs of older Arabic-speaking Australians. Australasian Journal on Ageing, 32(1), 28-33. [More Information]
  • Williams, C., Maher, C., Latimer, J., McLachlan, A., Hancock, M., Day, R., Billot, L., Lin, C. (2013). PACE - the first placebo controlled trial of paracetamol for acute low back pain: statistical analysis plan. Trials, 14(1), 1-9. [More Information]
  • Black, L., McLachlan, A., Griffith, J., Higgins, D., Gillett, A., Krockenberger, M., Govendir, M. (2013). Pharmacokinetics of chloramphenicol following administration of intravenous and subcutaneous chloramphenicol sodium succinate, and subcutaneous chloramphenicol, to koalas (Phascolarctos cinereus). Journal of Veterinary Pharmacology and Therapeutics, 36(5), 478-485. [More Information]
  • Black, L., McLachlan, A., Griffith, J., Higgins, D., Gillett, A., Krockenberger, M., Govendir, M. (2013). Pharmacokinetics of chloramphenicol in koalas (Phascolarctos cinereus). Wildlife Disease Assoc, Australasia Conference, N/A: N/A.
  • Johnston, C., Kirkpatrick, C., McLachlan, A., Hilmer, S. (2013). Physiologically Based Pharmacokinetic Modeling at the Extremes of Age. Clinical Pharmacology and Therapeutics, 93(2), 148-148. [More Information]
  • Mathieson, S., Maher, C., McLachlan, A., Latimer, J., Koes, B., Hancock, M., Harris, I., O Day, R., Pik, J., Jan, S., Billot, L., Lin, C. (2013). PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. Trials, 14(1), 1-8. [More Information]
  • Dolton, M., McLachlan, A. (2013). Reply to "What Types of Candida Infections Should Be Included When Evaluating Breakthrough Infections during Posaconazole Prophylaxis?". Antimicrobial Agents and Chemotherapy, 57(6), 2906-2906. [More Information]
  • Lowres, N., Neubeck, A., Redfern, J., McLachlan, A., Krass, I., Bennett, A., Briffa, T., Salkeld, G., Brieger, D., Sy, R., Bauman, A., Freedman, B. (2013). Screening Education and Recognition in Community Pharmacies of Atrial Fibrillation to Prevent stroke (SEARCH-AF Stroke Prevention Study). 61st Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ) 2013, Gold Coast, Queensland, Australia. [More Information]
  • Gnjidic, D., Le Couteur, D., Blyth, F., Travison, T., Rogers, K., Naganathan, V., Cumming, R., Waite, L., Seibel, M., Handelsman, D., McLachlan, A., Hilmer, S. (2013). Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open, 3(3), 1-10. [More Information]
  • Dolton, M., Ray, J., McLachlan, A. (2013). Telaprevir and Boceprevir: A Potential Role for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 35(3), 414-415. [More Information]
  • Saqf el Hait, S., Basheti, I., McLachlan, A., Overland, J., Chaar, B. (2013). The role of pharmacists in the management of Arabic-speaking people with diabetes mellitus: A systematic review. Journal of Pharmaceutical Health Services Research, 4(4), 239-248. [More Information]
  • Phalen, D., Frimberger, A., Pyecroft, S., Peck, S., Harmsen, C., Lola, S., De Mello Mattos, B., Li, K., McLachlan, A., Moore, A. (2013). Vincristine Chemotherapy Trials and Pharmacokinetics in Tasmanian Devils with Tasmanian Devil Facial Tumor Disease. PLoS One, 8(6), 1-7. [More Information]

2012

  • Lehnbom, E., McLachlan, A., Brien, J. (2012). A qualitative study of Australians' opinions about personally controlled electronic health records. Studies in Health Technology and Informatics, 178, 105-110. [More Information]
  • Le Couteur, D., Robinson, M., Leverton, A., Creasey, H., Waite, L., Atkins, K., McLachlan, A. (2012). Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease. Australasian Journal on Ageing, 31(3), 164-169. [More Information]
  • Le Couteur, D., McLachlan, A., Quinn, R., Simpson, S., De Cabo, R. (2012). Aging biology and novel targets for drug discovery. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 67A(2), 168-174. [More Information]
  • Le Couteur, D., McLachlan, A., De Cabo, R. (2012). Aging, Drugs, and Drug Metabolism. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 67A(2), 137-139. [More Information]
  • Robertson, J., Santoso, B., Holloway, K., Dartnell, J., Tisocki, K., McLachlan, A., Smith, A. (2012). Asia Pacific Conference on National Medicines Policies. Australian Prescriber, 35(6), 190-193.
  • Giam, J., McLachlan, A., Krass, I. (2012). Characterizing specialized compounding in community pharmacies. Research in Social and Administrative Pharmacy, 8(3), 240-252. [More Information]
  • McLachlan, A., Pont, L. (2012). Drug Metabolism in Older People - A Key Consideration in Achieving Optimal Outcomes With Medicines. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 67A(2), 175-180. [More Information]
  • Pinto, R., Maher, C., Ferreira, M., Ferreira, P., Hancock, M., Oliveira, V., McLachlan, A., Koes, B. (2012). Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. BMJ, 344, 1-15. [More Information]
  • Pinto, R., Maher, C., Ferreira, M., Hancock, M., Oliveira, V., McLachlan, A., Koes, B., Ferreira, P. (2012). Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Annals of Internal Medicine, 157(12), 865-877. [More Information]
  • Dolton, M., Roufogalis, B., McLachlan, A. (2012). Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion-Transporting Polypeptides. Clinical Pharmacology and Therapeutics, 92(5), 622-630. [More Information]
  • Gnjidic, D., Hilmer, S., Blyth, F., Naganathan, V., Cumming, R., Handelsman, D., McLachlan, A., Abernethy, D., Banks, E., Le Couteur, D. (2012). High-Risk Prescribing and Incidence of Frailty Among Older Community-Dwelling Men. Clinical Pharmacology and Therapeutics, 91(3), 521-528. [More Information]
  • Bell, S., Le Couteur, D., McLachlan, A., Chen, T., Moles, R., Basger, B., Hilmer, S. (2012). Improving medicine selection for older people: Do we need an Australian classification for inappropriate medicines use? Australian Family Physician, 41(1/2), 9-10. [More Information]
  • Perera, V., Gross, A., McLachlan, A. (2012). Influence of Environmental and Genetic Factors on CYP1A2 Activity in Individuals of South Asian and European Ancestry. Clinical Pharmacology and Therapeutics, 92(4), 511-519. [More Information]
  • Clarke, S., McLachlan, A. (2012). Interaction Between Complementary and Alternative Medicines and Conventional Medicines. In Olver, I and Robotin, M (Eds.), Perspectives on Complementary and Alternative Medicines, (pp. 227-259). London: Imperial College Press.
  • Rittau, A., McLachlan, A. (2012). Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling. Journal of Pharmacy and Pharmacology, 64(5), 705-711. [More Information]
  • Perera, V., Gross, A., McLachlan, A. (2012). Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe. Current Drug Metabolism, 13(5), 667-678. [More Information]
  • Dolton, M., Ray, J., Chen, S., Ng, K., Pont, L., McLachlan, A. (2012). Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response and Factors Affecting Concentration. Antimicrobial Agents and Chemotherapy, 56(11), 5503-5510. [More Information]
  • Dolton, M., Ray, J., Chen, S., Ng, K., Pont, L., McLachlan, A. (2012). Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 56(9), 4793-4799. [More Information]
  • Gnjidic, D., Hilmer, S., Blyth, F., Naganathan, V., Waite, L., Seibel, M., McLachlan, A., Cumming, R., Handelsman, D., Le Couteur, D. (2012). Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of Clinical Epidemiology, 65(9), 989-995. [More Information]
  • Dolton, M., Ray, J., Marriott, D., McLachlan, A. (2012). Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrobial Agents and Chemotherapy, 56(6), 2806-2813. [More Information]
  • Dolton, M., Pont, L., Stevens, G., McLachlan, A. (2012). Prevalence of potentially harmful drug interactions in older people in Australian aged-care facilities. Journal of Pharmacy Practice and Research, 42(1), 33-36.
  • Lowres, N., Freedman, B., Redfern, J., McLachlan, A., Krass, I., Bennett, A., Briffa, T., Bauman, A., Neubeck, A. (2012). Screening Education And Recognition in Community pHarmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged >65 years (SEARCH-AF stroke prevention study): a cross-sectional study protocol. BMJ Open, 2(3), 1-6. [More Information]
  • Mitchell, S., Huizer-Pajkos, A., Cogger, V., McLachlan, A., Le Couteur, D., Jones, B., De Cabo, R., Hilmer, S. (2012). The Influence of Old Age and Poloxamer-407 on the Hepatic Disposition of Diazepam in the Isolated Perfused Rat Liver. Pharmacology: international journal of experimental and clinical pharmacology, 90(5-6), 233-241. [More Information]
  • Stocker, S., McLachlan, A., Savic, R., Kirkpatrick, C., Graham, G., Williams, K., Day, R. (2012). The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology, 74(3), 477-489. [More Information]

2011

  • Mitchell, S., Huizer-Pajkos, A., Cogger, V., McLachlan, A., Le Couteur, D., Jones, B., De Cabo, R., Hilmer, S. (2011). Age-Related Pseudocapillarization of the Liver Sinusoidal Endothelium Impairs the Hepatic Clearance of Acetaminophen in Rats. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 66A(4), 400-408. [More Information]
  • Phan, V., Tan, C., Rittau, A., Xu, H., McLachlan, A., Clarke, S. (2011). An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 7(11), 1395-1410. [More Information]
  • Stafford, L., Peterson, G., Bereznicki, L., Jackson, S., van Tienen, E., Angley, M., Bajorek, B., McLachlan, A., Mullan, J., Misan, G., et al (2011). Clinical Outcomes of a Collaborative, Home-Based Postdischarge Warfarin Management Service. The Annals of Pharmacotherapy, 45(3), 325-334. [More Information]
  • McLachlan, A., Bath, S., Naganathan, V., Hilmer, S., Le Couteur, D., Gibson, S., Blyth, F. (2011). Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. British Journal of Clinical Pharmacology, 71(3), 351-364. [More Information]
  • He, X., Clarke, S., McLachlan, A. (2011). Clinical pharmacology of chemotherapy agents in older people with cancer. Current Gerontology and Geriatrics Research, 2011, 628670-1-628670-6. [More Information]
  • Giam, J., McLachlan, A., Krass, I. (2011). Community pharmacy compounding-impact on professional status. International Journal of Clinical Pharmacy, 33(2), 177-182. [More Information]
  • Le Couteur, D., Banks, E., Gnjidic, D., McLachlan, A. (2011). Deprescribing. Australian Prescriber, 34(6), 182-185.
  • Chaar, B., Brien, J., Hanrahan, J., McLachlan, A., Penm, J., Pont, L. (2011). Experimental Education in Australian Pharmacy: Preceptors' Perspectives. Pharmacy Education, 11(1), 166-171.
  • Clarke, S., McLachlan, A. (2011). Interaction between complementary and alternative medicine with conventional anti-cancer medicine. Cancer Forum, 35(1), 18-23.
  • Fois, R., Huynh, K., Chen, T., McLachlan, A., Lalor, D., Aslani, P. (2011). Patient safety culture climate among Australian community pharmacies. 2011 Primary Health Care Research Conference, Brisbane: Primary Health Care Research and Information Service.
  • Stocker, S., Graham, G., McLachlan, A., Williams, K., Day, R. (2011). Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with Gout. Journal of Rheumatology, 38(5), 904-910. [More Information]
  • Perera, V., Gross, A., Xu, H., McLachlan, A. (2011). Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. Journal of Pharmacy and Pharmacology, 63(9), 1161-1168. [More Information]
  • Mitchell, S., Huizer-Pajkos, A., Cogger, V., McLachlan, A., Le Couteur, D., Hilmer, S. (2011). Poloxamer 407 Increases the Recovery of Paracetamol in the Isolated Perfused Rat Liver. Journal of Pharmaceutical Sciences, 100(1), 334-340. [More Information]

2010

  • Nishtala, S., McLachlan, A., Bell, J., Chen, T. (2010). A retrospective study of drug-related problems in Australian aged care homes: medication reviews involving pharmacists and general practitioners. Journal of Evaluation in Clinical Practice, 17, 97-103. [More Information]
  • Huynh, K., Chen, T., McLachlan, A., Lalor, D., Aslani, P., Fois, R. (2010). An assessment of patient safety culture climate among Australian community pharmacies. Australasian Pharmaceutical Science Association Annual Conference (2010). Australasian Pharmaceutical Science Association.
  • Williams, C., Maher, C., Hancock, M., McLachlan, A., McAuley, J., Latimer, J. (2010). Appropriate Discard of "Best" Practice Guidelines for Acute Low Back Pain. Archives of Internal Medicine, 170(12), 1088-1088.
  • Clarke, S., McLachlan, A., Brown, D., Carbonara, S., Kissane, R. (2010). Beyond Conventional Cancer Treatments: The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians. In Monica Robotin, Ian Olver and Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physician's Handbook, (pp. 285-315). London: Imperial College Press.
  • Perera, V., Gross, A., McLachlan, A. (2010). Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomedical Chromatography, 24(10), 1136-1144. [More Information]
  • McLachlan, A., Hilmer, S., Le Couteur, D. (2010). Dosing Errors: Age-Related Changes in Pharmacokinetics. In Susan Koch, F. Michael Gloth, and Rhonda Nay (Eds.), Medication Management in Older Adults: A Concise Guide for Clinicians, (pp. 127-135). New York: Springer Science + Business Media.
  • Wilk, V., Palmer, H., Stosic, R., McLachlan, A. (2010). Evidence and Practice in the Self-Management of Low Back Pain: Findings From an Australian Internet-based Survey. Clinical Journal of Pain, 26(6), 533-540. [More Information]
  • Le Couteur, D., Ford, G., McLachlan, A. (2010). Evidence, Ethics and Medication Management in Older People. Journal of Pharmacy Practice and Research, 40(2), 148-152.
  • Perera, V., Hilmer, S., McLachlan, A. (2010). Frailty should be assessed using validated scales. Drugs and Aging, 27(8), 687. [More Information]
  • McLachlan, A. (2010). Generic medicines literacy - minimising the potential for patient confusion. Medical Journal of Australia, 192(7), 368-369. [More Information]
  • Williams, C., Maher, C., Hancock, M., McAuley, J., McLachlan, A., Britt, H., Fahridin, S., Harrison, C., Latimer, J. (2010). Low Back Pain and Best Practice Care - A Survey of General Practice Physicians. Archives of Internal Medicine, 170(3), 271-277. [More Information]
  • Stocker, S., Franklin, M., Anderson, J., Pillans, P., Williams, K., McLachlan, A., Day, R., Taylor, P. (2010). Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 878, 2363-2368. [More Information]
  • McLachlan, A., Ramzan, I. (2010). Misuse of Formulations in the Aged Care Setting. In Susan Koch, F. Michael Gloth, and Rhonda Nay (Eds.), Medication Management in Older Adults: A Concise Guide for Clinicians, (pp. 95-104). New York: Springer Science + Business Media.
  • Williams, C., Latimer, J., Maher, C., McLachlan, A., Cooper, C., Hancock, M., Day, R., McAuley, J., Lin, C. (2010). PACE - The first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial. BMC Musculoskeletal Disorders, 11, 169-1-169-6. [More Information]
  • Mohammed Abdul, M., Jiang, X., Williams, K., Day, R., Roufogalis, B., Liauw, W., Xu, H., Matthias, A., Lehmann, R., McLachlan, A. (2010). Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. British Journal of Clinical Pharmacology, 69(5), 508-515. [More Information]
  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Joshua, D., et al (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69(5), 484-497. [More Information]
  • Zeng, L., Blair, E., Nath, C., Shaw, P., Earl, J., Stephen, K., Montgomery, K., Coakley, J., Hodson, E., Stormon, M., McLachlan, A. (2010). Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. British Journal of Clinical Pharmacology, 70(4), 567-579. [More Information]
  • Giam, J., McLachlan, A., Krass, I. (2010). Specialized compounding in community pharmacies: Organizational perspective. Journal of the American Pharmacists Association, 50, 354-361. [More Information]
  • Le Couteur, D., Kendig, H., Naganathan, V., McLachlan, A. (2010). The Ethics of Prescribing Medications to Older People. In Susan Koch, F. Michael Gloth, and Rhonda Nay (Eds.), Medication Management in Older Adults: A Concise Guide for Clinicians, (pp. 29-42). New York: Springer Science + Business Media.
  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2010). The participation of cytochrome P450 3A4 in clozapine biotransformation is detected in people with schizophrenia by high-throughput in vivo phenotyping. Journal of Clinical Psychopharmacology, 30(5), 629-631. [More Information]
  • Duque, G., Close, J., de Jager, J., Ebeling, P., Inderjeeth, C., Lord, S., McLachlan, A., Reid, I., Troen, B. (2010). Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention. Medical Journal of Australia, 193(3), 173-179. [More Information]
  • Dolton, M., Xu, H., Cheong, E., Maitz, P., Kennedy, P., Gottlieb, T., Buono, E., McLachlan, A. (2010). Vancomycin pharmacokinetics in patients with severe burn injuries. Burns, 36(4), 469-476. [More Information]

2009

  • Ghassabian, S., Chetty, M., Tattam, B., Glen, J., Rahme, J., Stankovic, Z., Ramzan, I., Murray, M., McLachlan, A. (2009). A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Therapeutic Drug Monitoring, 31(2), 239-246. [More Information]
  • Nishtala, S., Fois, R., McLachlan, A., Bell, J., Kelly, P., Chen, T. (2009). Anticholinergic Activity of Commonly Prescribed Medications and Neuropsychiatric Adverse Events in Older People. The Journal of Clinical Pharmacology, 49, 1176-1184. [More Information]
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Day, R., Davies, R. (2009). Can Predictors of Responders to NSAIDs be Identified in Patients with Acute Low Back Pain? 10th International Forum on Primary Care Research on Low Back Pain: LBP Forum X 2009, United States: Harvard School of Public Health.
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Day, R., Davies, R. (2009). Can predictors of response to NSAIDs Be identified in patients with acute low back pain? Clinical Journal of Pain, 25(8), 659-665. [More Information]
  • Mitchell, S., Hilmer, S., McLachlan, A. (2009). Clinical pharmacology of analgesics in old age and frailty. Reviews in Clinical Gerontology, 19(2), 103-118. [More Information]
  • Fois, R., Mewes, B., McLachlan, A., Ramzan, I. (2009). Compounded medicines and 'off label' prescribing - A case for more guidance. Australian Family Physician, 38(1/2), 16-20. [More Information]
  • Nishtala, S., McLachlan, A., Bell, J., Chen, T. (2009). Determinants of Antidepressant Medication Prescribing in Elderly Residents of Aged Care Homes in Australia: A Retrospective Study. The American Journal of Geriatric Pharmacotherapy: the peer-reviewed journal of geriatric drug therapy, 7(4), 210-219. [More Information]
  • Nishtala, S., McLachlan, A., Bell, J., Chen, T. (2009). Determinants of antipsychotic medication use among older people living in aged care homes in Australia. International Journal of Geriatric Psychiatry, , 1-9. [More Information]
  • Hong, P., Moore, M., McLachlan, A., Piquette-Miller, M., Xu, H., Clarke, S. (2009). Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 5(3), 243-257. [More Information]
  • Zeng, L., Nath, C., Shaw, P., Earl, J., McLachlan, A. (2009). HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. Biomedical Chromatography, 23(1), 92-100. [More Information]
  • Nishtala, S., Hilmer, S., McLachlan, A., Hannan, P., Chen, T. (2009). Impact of Residential Medication Management Reviews on Drug Burden Index in Aged-Care Homes - A Retrospective Analysis. Drugs and Aging, 26(8), 677-686. [More Information]
  • Xu, H., Murray, M., McLachlan, A. (2009). Influence of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Sulfonylurea Drugs. Current Drug Metabolism, 10(6), 643-658. [More Information]
  • Zeng, L., Nath, C., Blair, E., Shaw, P., Stephen, K., Earl, J., Coakley, J., McLachlan, A. (2009). Population Pharmacokinetics of Acyclovir in Children and Young People with Malignancy after Administration of Intravenous Acyclovir or Oral Valacyclovir. Antimicrobial Agents and Chemotherapy, 53(7), 2918-2927. [More Information]
  • Eriksson, C., McLachlan, A., Chen, T., Nishtala, S., Fois, R. (2009). Selective serotonin reuptake inhibitor therapy and neurological and psychiatric adverse events. Australasian Pharmaceutical Science Association (APSA) Annual Conference (2009) Aus-CRS Symposium, Mount Waverley, Melbourne, Australia: Australasian Pharmaceutical Science Association.
  • Williams, C., Maher, C., Hancock, M., McAuley, J., McLachlan, A., Britt, H., Latimer, J. (2009). Usual care of low back pain in primary care and a comparison to evidence-based guideline recommendations. Australian Physiotherapy Association Conference Week APA 2009, Australia: Australian Physiotherapy Association.
  • McLachlan, A., Hilmer, S., Le Couteur, D. (2009). Variability in response to medicines in older people: Phenotypic and genotypic factors. Clinical Pharmacology and Therapeutics, 85(4), 431-433. [More Information]

2008

  • Su, E., Naganathan, V., Fallah, H., Bajorek, B., McLachlan, A. (2008). Anticoagulation control in hospitalised patients on warfarin. Journal of Pharmacy Practice and Research, 38(4), 292-295.
  • McLachlan, A. (2008). Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Medical Journal of Australia, 188(7), 428-429.
  • Roos, J., Kirkpatrick, C., Tett, S., McLachlan, A., Duffull, S. (2008). Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. British Journal of Clinical Pharmacology, 66(4), 455-466. [More Information]
  • Xu, H., Williams, K., Liauw, W., Murray, M., Day, R., McLachlan, A. (2008). Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology, 153(7), 1579-1586. [More Information]
  • Giam, J., McLachlan, A. (2008). Extemporaneous product use in paediatric patients: a systematic review. International Journal of Pharmacy Practice, 16, 3-10.
  • Zeng, L., Nath, C., Shaw, P., Earl, J., McLachlan, A. (2008). HPLC-fluorescence assay for acyclovir in children. Biomedical Chromatography, 22(8), 879-887. [More Information]
  • Iyer, S., Naganathan, V., McLachlan, A., Le Couteur, D. (2008). Medication Withdrawal Trials in People Aged 65 Years and Older: A Systematic Review. Drugs and Aging, 25(12), 1021-1031. [More Information]
  • Aslani, P., El Samman, F., McLachlan, A., Chaar, B. (2008). Medicine information needs of older Arabic-speaking Australians. National Medicines Symposium 2008, Canberra: Pharmaceutical Health and Rational Use of Medicines Committee.
  • Mohammed Abdul, M., Jiang, X., Williams, K., Day, R., Roufogalis, B., Liauw, W., Xu, H., McLachlan, A. (2008). Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. British Journal of Pharmacology, 154(8), 1691-1700. [More Information]
  • Stocker, S., Williams, K., McLachlan, A., Graham, G., Day, R. (2008). Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clinical Pharmacokinetics, 47(2), 111-118. [More Information]
  • Jiang, X., Galettis, P., Links, M., Mitchell, P., McLachlan, A. (2008). Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. British Journal of Clinical Pharmacology, 65(3), 326-333. [More Information]
  • Nishtala, S., McLachlan, A., Bell, J., Chen, T. (2008). Psychotropic prescribing in long-term care facilities: Impact of medication reviews and educational interventions. American Journal of Geriatric Psychiatry, 16(8), 621-632. [More Information]

2007

  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2007). Addition of NSAIDS and/or manipulation to advice and paracetamol does not speed recovery from acute low back pain. 9th International Forum on Primary Care Research on Low Back Pain: LBP Forum IX 2007.
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2007). Addition of NSAIDS and/or manipulation to advice and paracetamol does not speed recovery from acute low back pain. Musculoskeletal Physiotherapy Australia 15th Biennial conference 2007, Australia: Australian Physiotherapy Association.
  • Nath, C., McLachlan, A., Shaw, P., Coakley, J., Earl, J. (2007). Amphotericin B Dose Optimization in Children with Malignant Diseases. Chemotherapy, 53(2), 142-147. [More Information]
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2007). Assessment of diclofenac or spinal manipulation therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. The Lancet, 370(9599), 1638-1643. [More Information]
  • Day, R., Graham, G., Hicks, M., McLachlan, A., Stocker, S., Williams, K. (2007). Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clinical Pharmacokinetics, 46(8), 623-644. [More Information]
  • Hilmer, S., McLachlan, A., Le Couteur, D. (2007). Clinical pharmacology in the geriatric patient. Fundamental and Clinical Pharmacology, 21(3), 217-230. [More Information]
  • McLachlan, A. (2007). Community physiotherapy results in effective self-management of knee pain (commentary 2). Australian Journal of Physiotherapy, 53(1), 62-63.
  • Favaloro, E., Lloyd, J., Rowell, J., Baker, R., Rickard, K., Kershaw, G., Street, A., Scarff, K., Barrese, G., Maher, D., McLachlan, A. (2007). Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder - A randomised cross-over, multi-centre study. Thrombosis and Haemostasis, 97(6), 922-930. [More Information]
  • McLachlan, A., Ramzan, I., Milne, R. (2007). Frequently asked questions about generic medicines. Australian Prescriber, 30(2), 41-43.
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Pharmacology and Therapeutics, 82(1), 33-40. [More Information]
  • Bell, J., Aslani, P., McLachlan, A., Whitehead, P., Chen, T. (2007). Mental health case conferences in primary care: content and treatment decision making. Research in Social and Administrative Pharmacy, 3(1), 86-103. [More Information]
  • Hong, Y., Shaw, P., Tattam, B., Nath, C., Earl, J., Stephen, K., McLachlan, A. (2007). Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. European Journal of Clinical Pharmacology, 63(2), 165-172. [More Information]
  • Xu, H., Loboz, K., Gross, A., McLachlan, A. (2007). Stereoselective Analysis of Hydroxybupropion and Application to Drug Interaction Studies. Chirality, 19(3), 163-170. [More Information]
  • Favaloro, E., Kershaw, G., McLachlan, A., Lloyd, J. (2007). Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease. Seminars in Thrombosis and Hemostasis, 33(8), 745-758. [More Information]

2006

  • Loboz, K., Gross, A., Williams, K., Liauw, W., Day, R., Blievernicht, J., Zanger, U., McLachlan, A. (2006). Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity. Pharmacology and Therapeutics, 80(1), 75-84. [More Information]
  • Ray, J., Keogh, A., McLachlan, A. (2006). Decision Support Tool to Individualize Cyclosporine Dose in Stable, Long-term Heart Transplant Recipients Receiving Metabolic Inhibitors: Overcoming Limitations of Cyclosporine C2 Monitoring. Journal Of Heart And Lung Transplantation, 25(10), 1223-1229. [More Information]
  • Bell, J., Whitehead, P., Aslani, P., McLachlan, A., Chen, T. (2006). Drug-Related Problems in the Community Setting - Pharmacists' Findings and Recommendations for People with Mental Illnesses. Clinical Drug Investigation, 26(7), 415-425. [More Information]
  • Jiang, X., Blair, E., McLachlan, A. (2006). Investigations of the Effects of Herbal Medicines on Warfarin Response in Healthy Subjects: A Population Pharmacokinetic-Pharmacodynamic Modeling Approach. The Journal of Clinical Pharmacology, 46(11), 1370-1378. [More Information]
  • McLachlan, A., Ramzan, I. (2006). Meals and Medicines. Australian Prescriber, 29(2), 40-42.
  • Paradisis, M., Evans, N., Kluckow, M., Osborn, D., McLachlan, A. (2006). Pilot study of milrinone for low systemic blood flow in very preterm infants. The Journal of Pediatrics, 148(3), 306-313. [More Information]
  • Paradisis, M., Jiang, X., McLachlan, A., Evans, N., Kluckow, M., Osborn, D. (2006). Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition (e ADC - F and N), 92(3), F204-F209. [More Information]
  • Hong, Y., Shaw, P., Nath, C., Yadav, S., Stephen, K., Earl, J., McLachlan, A. (2006). Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrobial Agents and Chemotherapy, 50(3), 935-942. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455.
  • Gisev, N., Bell, J., McLachlan, A., Chetty, M., Chen, T. (2006). Psychiatric Drug Use Among Patients of a Community Mental Health Service: Patterns and Implications. Disease Management and Health Outcomes, 14(6), 369-376.

2005

  • Senner, A., Johnston, K., McLachlan, A. (2005). A Comparison of Peripheral and Centrally Collected Cyclosporine A Blood Levels in Pediatric Patients Undergoing Stem Cell Transplant. Oncology Nursing Forum, 32(1), 73-77. [More Information]
  • Ramzan, I., McLachlan, A. (2005). Anti-epileptics switching problem?. But where is the evidence? Australian Journal of Pharmacy, 86, 772-820.
  • Bell, J., McLachlan, A., Aslani, P., Whitehead, P., Chen, T. (2005). Community pharmacy services to optimise the use of medications for mental illness: a systematic review. Australia and New Zealand Health Policy, 2(29), 1-11. [More Information]
  • Jiang, X., Williams, K., Liauw, W., Ammit, A., Roufogalis, B., Duke, C., Day, R., McLachlan, A. (2005). Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology, 59(4), 425-432. [More Information]
  • Ramzan, I., McLachlan, A. (2005). Generic arguments. Australian Pharmacist, 24, 501-502.
  • Hong, Y., Ramzan, I., McLachlan, A. (2005). Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver. Journal of Pharmaceutical Sciences, 94(1), 169-176. [More Information]
  • Loboz, K., Gross, A., Ray, J., McLachlan, A. (2005). HPLC assay for bupropion and its major metabolites in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 823, 115-121. [More Information]
  • Tobin, P., Hong, Y., Seale, J., Rivory, L., McLachlan, A. (2005). Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. Journal of Pharmacy and Pharmacology, 57, 39-45. [More Information]
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2005). Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomised controlled trial. Faculty of Health Science Post Graduate Research Symposium 2005, Australia: University of Sydney.
  • Hancock, M., Maher, C., Latimer, J., McLachlan, A., Cooper, C., Day, R., Spindler, M., McAuley, J. (2005). Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomised controlled trial [ACTRN012605000036617]. BMC Musculoskeletal Disorders, 6, 57-1-57-6. [More Information]
  • Zahir, H., McLachlan, A., Nelson, A., McCaughan, G., Gleeson, M., Akhlaghi, F. (2005). Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients. Therapeutic Drug Monitoring, 27(4), 422-430. [More Information]
  • Ray, J., Marriott, D., Bloch, M., McLachlan, A. (2005). Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. British Journal of Clinical Pharmacology, 60(3), 291-299. [More Information]

2004

  • Pett, S., Williams, L., Day, R., Lloyd, A., Carr, A., Clezy, K., Emery, S., Kaplan, E., McPhee, D., McLachlan, A., et al (2004). A Phase I Study Of The Pharmacokinetics And Safety Of Passive Immunotherapy With Caprine Anti-Hiv Antibodies, (Pe)Hrg214, In Hiv-1-Infected Individuals. HIV Clinical Trials, 5(2), 91-98.
  • Pearce, G., McLachlan, A., Ramzan, I. (2004). Bioequivalence: How, Why and What Does it Really Mean? Journal of Pharmacy Practice and Research, 34(3), 195-200.
  • Zahir, H., McCaughan, G., Gleeson, M., Nand, R., McLachlan, A. (2004). Changes In Tacrolimus Distribution In Blood And Plasma Protein Binding Following Liver Transplantation. Therapeutic Drug Monitoring, 26(5), 506-515.
  • Hong, Y., Ramzan, I., McLachlan, A. (2004). Disposition Of Amphotericin B In The Isolated Perfused Rat Liver. Journal of Pharmacy and Pharmacology, 56(1), 35-41.
  • Mukhtar, S., Olsen, W., McLachlan, A. (2004). Dissolution Of Extemporaneous Paracetamol Capsules. Journal of Pharmacy Practice and Research, 34(4), 276-281.
  • Jiang, X., Williams, K., Liauw, W., Ammit, A., Roufogalis, B., Duke, C., Day, R., McLachlan, A. (2004). Effect Of St John's Wort And Ginseng On The Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects. British Journal of Clinical Pharmacology, 57(5), 592-599.
  • Zahir, H., McCaughan, G., Gleeson, M., Nand, R., McLachlan, A. (2004). Factors Affecting Variability In Distribution Of Tacrolimus In Liver Transplant Recipients. British Journal of Clinical Pharmacology, 57(3), 298-309.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2004). Herb-Drug Interactions: An Evidence Based Approach. Current Medicinal Chemistry, 11(11), 1513-1525.
  • Blair, E., Rivory, L., Clarke, S., McLachlan, A. (2004). Population Pharmacokinetics Of Raltitrexed In Patients With Advanced Solid Tumours. British Journal of Clinical Pharmacology, 57(4), 416-426.
  • Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53.

2003

  • Ray, J., Keogh, A., McLachlan, A., Akhlaghi, F. (2003). Cyclosporin c2 and c0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. Journal Of Heart And Lung Transplantation, 22(7), 715-722.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). Garlic-drug interactions. The Journal of Complementary Medicine, 11, 57-59.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). Ginkgo biloba interactions. The Journal of Complementary Medicine, 11, 70-72.
  • Sasongko, L., Williams, K., Day, R., McLachlan, A. (2003). Human subcutaneous tisue distribution of fluconazole: comparison of microdialysis and suction blister techniques. British Journal of Clinical Pharmacology, 56(5), 551-561.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). Interaction or over-reaction? Journal of Alternative and Complementary Medicine: research on paradigm, practice, and policy, 11, 60-61.
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). Liquorice-drug interactions. The Journal of Complementary Medicine, 11, 40-43.
  • Wren, B., Day, R., McLachlan, A., Williams, K. (2003). Pharmacokinetcs of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. Climacteric, 6(2), 104-111.
  • Tett, S., Kirkpatrick, C., Gross, A., McLachlan, A. (2003). Principles and clinical application of assessing alterations in renal elimination pathways. Clinical Pharmacokinetics, 42(14), 1193-1211. [More Information]
  • Coxeter, P., McLachlan, A., Duke, C., Roufogalis, B. (2003). St John's wort interactions. Journal of Alternative and Complementary Medicine: research on paradigm, practice, and policy, 11, 66-68.
  • Bell, J., Aslani, P., McLachlan, A., Whitehead, P., Chen, T., Penrose-Wall, J. (2003). The role of the community pharmacist in Home Medicine Reviews and case conferences for consumers with mental disorders. Australian Journal of Pharmacy, 11, 716-719.

2002

  • Bell, J., McLachlan, A., Chen, T. (2002). Evidence based assessment of pharmaceutical interventions for the treatment and prevention of osteoporosis. 12th International Social Pharmacy Workshop in Australia, Sweden: Swedish Pharmaceutical Press.
  • Firth, S., McDougall, F., McLachlan, A., Baxter, R. (2002). Impaired Blockade of Insulin-Like Growth Factor I (IGF-I)-Induced Hypoglycemia by IGF Binding Protein-3 Analog with Reduced Ternary Complex-Forming Ability. Endocrinology, 143(5), 1669-1676.
  • Hosseini Yeganeh, M., McLachlan, A. (2002). In-vitro distribution of terbinafine in rat and human blood. Journal of Pharmacy and Pharmacology, 54(2), 277-281.
  • Sasongko, L., Ramzan, I., Williams, K., McLachlan, A. (2002). Muscle distribution of the neuromuscular blocker gallami using microdialysis. Journal of Pharmaceutical Sciences, 91(3), 769-775. [More Information]
  • Hosseini Yeganeh, M., McLachlan, A. (2002). Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrobial Agents and Chemotherapy, 46(7), 2219-2228.

2001

  • McLachlan, A., Gross, A., Beal, J., Minns,, I., Tett, S. (2001). Analytical validation for a series of marker compounds used to assess renal drug elimination processes. Therapeutic Drug Monitoring, 23, 39-46.
  • Sasongko, L., Ramzan, I., McLachlan, A., Williams, K. (2001). Application of a high-performance liquid chromatographic assay for the neuromuscular blocker gallamine to analysis of rat plasma, muscle and microdialysate samples. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 754, 467-475.
  • Duke, C., Goh, P., McLachlan, A., Roufogalis, B. (2001). Complementary Medicines. Australia: Pharmaceutical Society of Australia.
  • Sasongko, L., McLachlan, A., Williams, K., Day, R. (2001). Human skin tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. Australasian Society of Clinical nd Experimental Pharmacologists and Toxicologists Annual Scientific Meeting, : World Scientific Publishing.
  • Akhalaghi, F., McLachlan, A., Keogh, A., Kaan, A. (2001). Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. Journal Of Heart And Lung Transplantation, 20(4), 431-438.
  • Nath, C., McLachlan, A., Shaw, P., Gunning,, R., Earl, J. (2001). Population pharmacokinetics of amphotericin B in children with malignant diseases. British Journal of Clinical Pharmacology, 52, 671-680.
  • McLachlan, A., Gross, A., Minns,, I., Beal, J., Tett, S. (2001). Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. British Journal of Clinical Pharmacology, 51, 547-555.
  • Hosseini Yeganeh, M., McLachlan, A. (2001). Tissue distribution of terbinafine in rats. Journal of Pharmaceutical Sciences, 90(11), 1817-1828.
  • Sainsbury, E., McLachlan, A., Aslani, P. (2001). Tools of the trade: Preparing pharmacists for professional practice.
  • Zahir, H., Nand, R., Brown, K., Tattam, B., McLachlan, A. (2001). Validation of methods to study the distribution and protein binding of tacrolimus in human blood. Journal of Pharmacological and Toxicological Methods, 46, 27-35.

For support on your academic profile contact .